Do You Really Need a Liquid Biopsy Test? What to Know Before Starting Cancer Treatment
A cancer diagnosis can bring a flood of decisions. You may be wondering whether another test could provide a clearer picture before treatment begins, and whether a liquid biopsy is the right next step.
The honest answer: sometimes it can help, but it is not necessary or right for every person. A liquid biopsy can offer useful information about certain tumor-related genetic changes, especially when a tissue sample is difficult to obtain or when a treatment decision depends on a specific biomarker. But it does not replace every role of a traditional biopsy, and a blood test that finds no change does not always mean that no relevant change is present.
You deserve an explanation of what a test can, and cannot, tell you, so you can discuss your options with your care team without feeling rushed.
What is a liquid biopsy?
A liquid biopsy is a test performed on a blood sample. Some tests look for circulating tumor DNA, often called ctDNA: small fragments of genetic material that cancer cells may release into the bloodstream. Depending on the test, it may examine other features, too. Not every liquid biopsy measures the same things, so it is worth asking exactly what the test looks for.
The goal is often to identify genetic changes, or biomarkers, that may help guide treatment choices. Some targeted medicines are designed for cancers with particular biomarkers. A liquid biopsy may help a clinician look for those changes without taking a new sample directly from a tumor.
A blood draw is generally less invasive than a procedure to collect tumor tissue, and it may be easier to repeat. But “less invasive” does not mean “complete in every case.” The test can only report what its particular method is able to detect in the sample.
When might it be useful before treatment?
Your oncology team may consider liquid biopsy when a result could help answer a specific treatment question. For example, it may be discussed when:
- A tissue sample is unavailable, too small, or difficult or unsafe to obtain.
- A clinician needs to look for certain biomarkers that may affect treatment options.
- A blood-based result could complement tissue testing or provide additional information.
Some blood-based tests have FDA-authorized uses as companion diagnostics for specific cancer biomarkers and medicines. A companion diagnostic is a test intended to help identify whether a particular treatment may be appropriate under its labeled use. The FDA’s current list of authorized companion diagnostic devices shows why the details matter: the use depends on the specific test, cancer, biomarker, and medicine.
A result is not a treatment plan by itself. Your clinician needs to interpret it alongside your diagnosis, cancer type, stage, medical history, and goals.
Why it may not replace a tissue biopsy
A tissue biopsy can help establish what kind of cancer is present by allowing specialists to examine cells and the structure of the tissue. Depending on the cancer, tissue may also provide information about proteins or other features that a blood test does not assess in the same way.
Liquid biopsy answers a different kind of question. It can look for certain tumor-related signals in the blood, but it may not capture the full picture of the cancer or provide the information needed to make the diagnosis.
That is why it helps to think of liquid biopsy as one possible source of information, not a universal substitute for pathology, imaging, or tissue-based testing. The National Cancer Institute’s overview of FDA-approved blood tests for tumor profiling describes situations where blood testing may be useful, while also explaining that tissue results can remain important.
What if the result is negative?
This is one of the most important questions to ask before testing. A negative liquid-biopsy result may mean that the test did not detect a relevant change in that blood sample. It may not mean the tumor definitely lacks that change.
Some tumors release very little ctDNA into the bloodstream. The amount detectable can vary with factors such as tumor size, location, and biology. The test also has technical limits: it can only detect the features its assay is designed to find, within its sensitivity.
The NCI explains that low levels of tumor DNA can make detection difficult, particularly in some circumstances, and that a blood test may fail to find a change that is present in the cancer. You can read more in its article on factors that affect ctDNA detection.
If a result is negative, ask your oncology team whether tissue testing, or another step, is still appropriate. The answer will depend on your cancer and the reason the test was ordered. A negative result should be interpreted in context, not in isolation.
Questions to ask before you decide
You do not need to be an expert in genomics to take part in this decision. Ask your doctor to explain the test in plain language. You might ask:
- What question are we hoping this test will answer?
- Could the result change my treatment options or timing?
- What does this specific test measure, and what does it not measure?
- If the result is negative or inconclusive, what would we do next?
- How will this result be considered alongside tissue pathology and imaging?
- What are the cost, coverage, and turnaround-time considerations?
These questions can help you understand whether testing is likely to be useful in your situation. They can also make space for a thoughtful conversation about your priorities and concerns.
A personalized approach should include the whole person
At First Nations Clinic, we believe you deserve care that looks beyond a statistical guess and considers your individual biology, your values, and your goals. Our cancer-care approach describes liquid-biopsy profiling as one part of a personalized care process. Whether a particular test is appropriate, and how its results should be used, depends on your circumstances and should be discussed with qualified clinicians.
Precision medicine can support better-informed conversations. It cannot promise that a particular test will identify a treatment, or that a treatment will work. It is also important to review any proposed care with your oncology team and not delay or stop recommended treatment while waiting for a test or exploring other options.
We also believe care can honor spirit, soul, and body. From a Christian perspective, prayer and Scripture can offer comfort and grounding as you face uncertainty. They do not replace medical evaluation or treatment. We respect that people draw strength from different beliefs and traditions, and we welcome compassionate conversations that make room for what matters to you.
You can make the decision one step at a time
So, do you really need a liquid biopsy test before starting cancer treatment? Not automatically. It may be helpful when the information could guide a specific decision, but it is not a stand-alone answer, and it is not right for everyone. Ask what the test is meant to clarify, how the result will be interpreted, and what happens if it does not detect a tumor-related change.
You deserve careful explanations, clear choices, and support as you consider your next step. If you would like to learn how First Nations Clinic approaches personalized cancer care, you can start a conversation with our team.
This article is for educational purposes and is not a substitute for medical advice, diagnosis, or treatment. Discuss testing and treatment decisions with your licensed healthcare professionals.